PF 3084014 hydrobromide
Potent γ-secretase inhibitor (IC50 values are 1.2 and 6.2 nM in whole cell and cell-free assays, respectively). Reduces Aβ in brain, CSF and plasma in mice and guinea pigs.
Sold for research purposes under agreement from Pfizer Inc.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|water||6.51||10mM with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 651.47. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.53 mL||7.67 mL||15.35 mL|
|5 mM||0.31 mL||1.53 mL||3.07 mL|
|10 mM||0.15 mL||0.77 mL||1.53 mL|
|50 mM||0.03 mL||0.15 mL||0.31 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Lanz et al (2010) Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014. J.Pharmacol.Exp.Ther. 334 269 PMID: 20363853
If you know of a relevant reference for PF 3084014 hydrobromide, please let us know.
View Related Products by Product Action
Keywords: PF 3084014 hydrobromide, supplier, PF3084014, hydrobromide, gamma, secretase, inhibitors, inhibits, γ, Abeta, amyloid, β, Gamma-Secretase, Tocris Bioscience
Citations for PF 3084014 hydrobromide
Citations are publications that use Tocris products.
Currently there are no citations for PF 3084014 hydrobromide. Do you know of a great paper that uses PF 3084014 hydrobromide from Tocris? If so please let us know.
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.